U.S. markets close in 4 hours 7 minutes
  • S&P 500

    4,057.75
    -18.82 (-0.46%)
     
  • Dow 30

    34,323.86
    -71.15 (-0.21%)
     
  • Nasdaq

    11,404.25
    -78.20 (-0.68%)
     
  • Russell 2000

    1,881.76
    +0.08 (+0.00%)
     
  • Crude Oil

    81.50
    +0.28 (+0.34%)
     
  • Gold

    1,806.90
    -8.30 (-0.46%)
     
  • Silver

    23.33
    +0.48 (+2.12%)
     
  • EUR/USD

    1.0513
    -0.0015 (-0.15%)
     
  • 10-Yr Bond

    3.5850
    +0.0560 (+1.59%)
     
  • GBP/USD

    1.2280
    +0.0024 (+0.20%)
     
  • USD/JPY

    134.9750
    -0.3310 (-0.24%)
     
  • BTC-USD

    16,935.06
    -54.14 (-0.32%)
     
  • CMC Crypto 200

    401.96
    +0.54 (+0.13%)
     
  • FTSE 100

    7,556.23
    -2.26 (-0.03%)
     
  • Nikkei 225

    27,777.90
    -448.18 (-1.59%)
     

Investors in Poseida Therapeutics (NASDAQ:PSTX) have unfortunately lost 58% over the last year

Poseida Therapeutics, Inc. (NASDAQ:PSTX) shareholders will doubtless be very grateful to see the share price up 58% in the last quarter. But that isn't much consolation to those who have suffered through the declines of the last year. Like a receding glacier in a warming world, the share price has melted 58% in that period. The share price recovery is not so impressive when you consider the fall. You could argue that the sell-off was too severe.

Now let's have a look at the company's fundamentals, and see if the long term shareholder return has matched the performance of the underlying business.

See our latest analysis for Poseida Therapeutics

Given that Poseida Therapeutics didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually expect strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

earnings-and-revenue-growth
earnings-and-revenue-growth

Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

A Different Perspective

Poseida Therapeutics shareholders are down 58% for the year, even worse than the market loss of 16%. There's no doubt that's a disappointment, but the stock may well have fared better in a stronger market. Putting aside the last twelve months, it's good to see the share price has rebounded by 58%, in the last ninety days. Let's just hope this isn't the widely-feared 'dead cat bounce' (which would indicate further declines to come). While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example - Poseida Therapeutics has 5 warning signs (and 3 which don't sit too well with us) we think you should know about.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here